The TETON programme consisted of two replicate, 52-week, randomised, double-blind, placebo-controlled, phase 3 studies, investigating inhaled treprostinil in the treatment of idiopathic pulmonary fibrosis (NCT04708782, NCT05255991). touchRESPIRATORY were delighted to talk with Dr. Steven D. Nathan (Inova Fairfax Hospital, Annandale, VA, USA) to discuss the aims, design, eligibility criteria and endpoints being investigated in the TETON clinical trial program and when we can expect the findings.
The abstract ‘Study Design and Rationale for the TETON Phase 3 Clinical Trials of Inhaled Treprostinil in the Treatment of Idiopathic Pulmonary Fibrosis.‘ (Abstract number: PA1934) was presented at ERS 2022, 4–6 September, 2022.
Questions
- Could you give us a brief overview of the TETON clinical trial program?
- What are the eligibility criteria of the studies?
- What are the primary and secondary endpoints of the studies?
- When are the first results expected?
Disclosures: Steven Nathan discloses consulting for United Therapeutics; serving on advisory boards for United Therapeutics; receiving honoraria from United Therapeutics; and participating in speaker’s bureaus for United Therapeutics.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the ERS meeting 2022.
